Please login to the form below

Not currently logged in
Email:
Password:

polycystic kidney disease

This page shows the latest polycystic kidney disease news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Otsuka gains European nod for Jinarc extension. The European Commission has approved a label extension for Jinarc (tolvaptan) to include adult patients with CKD stage 4 Autosomal Dominant Polycystic Kidney Disease ... Jinarc is the only drug treatment

Latest news

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Making good practice common practice in rare disease

    However, fatigue scores can’t be explained purely by disease activity and depression. ... 2015 - 88% of people with early-stage autosomal dominant polycystic kidney disease (ADPKD), reported physical symptoms including pain and general malaise.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics